Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants

Currently, direct oral anticoagulants (DOACs) should be preferred when prescribing anticoagulant therapy to atrial fibrillation patients because of their lower potential for interactions and risk of bleeding than warfarin. However, in the absence of standardized laboratory tests and a specific antidote (except dabigatran), prescribing and monitoring DOAC therapy remains a challenge for clinicians and patients. The present review focuses on the problems of DOAC laboratory evaluation, indications, and prospects for its use. Routine coagulation tests including activated partial thromboplastin time, prothrombin time and thrombin time are not recommended for DOAC therapy. Currently, there are specific coagulation tests (anti-Xa activity factor determination for apixaban/ rivaroxaban and diluted thrombin time for dabigatran) that allow judging the presence of the drug in the blood. According to current recommendations, these tests should be used only to assess anticoagulant concentrations and not to adjust doses and decide on the timing of withdrawal before invasive intervention. Nevertheless, the issue of determining DOAC concentration during invasive interventions, the need for which only increases with age, is most relevant. Also a possible additional factor that may alter the bioavailability and pharmacokinetics of DOAC and be taken into account in the evaluation of laboratory activity is the presence of chronic renal disease, hepatic insufficiency, low or excess body weight. The use of specific coagulation tests for patients undergoing elective and urgent surgery among special categories of patients (with chronic kidney disease, low or excess body weight, renal failure) is promising.

1. Schulman S., Crowther M.A. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016–3023. https://doi.org/10.1182/blood-2011-10-378950.

2. Garcia D., Barrett Y.C., Ramacciotti E., Weitz J.I. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11(2):245–252. https://doi.org/10.1111/jth.12096.

3. Castellone D.D., van Cott E.M. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010;85(3):185–187. https://doi.org/10.1002/ajh.21607.

4. Van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., Clemens A. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127. https://doi.org/10.1160/TH09-11-0758.

5. Hapgood G., Butler J., Malan E., Chunilal S., Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost. 2013;110(2):308–315. https://doi.org/10.1160/TH13-04-0301.

6. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogné J.M., Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost. 2013;110(4):723–731. https://doi.org/10.1160/TH13-04-0274.

7. Tripodi A. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost. 2013;11(4):576–578. https://doi.org/10.1111/jth.12166.

8. Samama M.M. Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay. J Thromb Haemost. 2013;11(4):579–580. https://doi.org/10.1111/jth.12165.

9. Douxfils J., Chatelain C., Chatelain B., Dogné J.M., Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110(2):283–294. https://doi.org/10.1160/TH12-12-0898.

10. Shaw J.R., Li N., Vanassche T., Coppens M., Spyropoulos A.C., Syed S. et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020;4(15):3520–3527. https://doi.org/10.1182/bloodadvances.2020002335.

11. Godier A., Dincq A.S., Martin A.C., Radu A., Leblanc I., Antona M. et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017;38(31):2431–2439. https://doi.org/10.1093/eurheartj/ehx403.

12. Fox V., Kleikamp A., Dittrich M., Zittermann A., Flieder T., Knabbe C. et al. Direct oral anticoagulants and cardiac surgery: A descriptive study of preoperative management and postoperative outcomes. J Thorac Cardiovasc Surg. 2021;161(5):1864–1874.e2. https://doi.org/10.1016/j.jtcvs.2019.11.119.

13. Douketis J.D., Wang G., Chan N., Eikelboom J.W., Syed S., Barty R. et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016;14(1):89–97. https://doi.org/10.1111/jth.13178.

14. Hankey G.J., Eikelboom J.W. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436–1450. https://doi.org/10.1161/circulationaha.110.004424.

15. Reilly P.A., Lehr T., Haertter S., Connolly S.J., Yusuf S., Eikelboom J.W. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–328. https://doi.org/10.1016/j.jacc.2013.07.104.

16. Cirincione B., Kowalski K., Nielsen J., Roy A., Thanneer N., Byon W. et al. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728–738. https://doi.org/10.1002/psp4.12347.

17. Schellings M.W., Boonen K., Schmitz E.M., Jonkers F., van den Heuvel D.J., Besselaar A. et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res. 2016;139:128–134. https://doi.org/10.1016/j.thromres.2016.01.012.

18. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561.

19. Qamar A., Vaduganathan M., Greenberger N.J., Giugliano R.P. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol. 2018;71(19):2162–2175. https://doi.org/10.1016/j.jacc.2018.03.023.

20. Kubitza D., Roth A., Becka M., Alatrach A., Halabi A., Hinrichsen H., Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89–98. https://doi.org/10.1111/bcp.12054.

21. Martinez M., Tandra A., Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2014;60(1):425–426. https://doi.org/10.1002/hep.26998.

22. Potze W., Arshad F., Adelmeijer J., Blokzijl H., van den Berg A.P., Meijers J.C. et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS ONE. 2014;9(2):e88390. https://doi.org/10.1371/journal.pone.0088390.

23. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. https://doi.org/10.1056/NEJMoa1009638.

24. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. https://doi.org/10.1056/NEJMoa1107039.

25. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561.